Skip to Content
Merck

Lanatoside C Promotes Foam Cell Formation and Atherosclerosis.

Scientific reports (2016-01-30)
Huairui Shi, Xiaobo Mao, Yucheng Zhong, Yuzhou Liu, Xiaoqi Zhao, Kunwu Yu, Ruirui Zhu, Yuzhen Wei, Jianghao Zhu, Haitao Sun, Yi Mao, Qiutang Zeng
ABSTRACT

Lanatoside C's impact on atherosclerosis is poorly understood. The present study was conducted to determine whether lanatoside C affects the development of atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice. ApoE(-/-) mice were administered either phosphate-buffered saline (PBS) containing 0.1% DMSO (the vehicle control group) or lanatoside C at low (1 mg/kg per day) or high (2 mg/kg per day) doses, and fed a Western diet for 12 weeks. Lanatoside C dose-dependently aggravated the development of atherosclerosis in the ApoE(-/-) mice compared with the vehicle control group. In an effort to determine the mechanism by which lanatoside C increased atherosclerosis, we found that lanatoside C significantly promoted the uptake of oxidised low-density lipoprotein (oxLDL) and increased foam-cell formation by upregulation of scavenger receptor class A (SR-A) and the class B scavenger receptor (CD36) in macrophages. Meanwhile, the effects of lanatoside C were abolished using small interfering RNA (siRNA) inhibition of peroxisome proliferator-activated receptors β/δ (PPARβ/δ). Overall, our data demonstrate that lanatoside C aggravates the development of atherosclerosis by inducing PPARβ/δ expression, which mediates upregulation of SR-A and CD36, and promotes oxLDL uptake and foam-cell formation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Apolipoprotein A−I human, recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)